Profile data is unavailable for this security.
About the company
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
- Revenue in USD (TTM)2.24bn
- Net income in USD798.86m
- Incorporated2020
- Employees89.00
- LocationRoyalty Pharma PLC110 East 59th StreetNEW YORK 10022United StatesUSA
- Phone+1 (212) 883-0200
- Websitehttps://www.royaltypharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | 124.80m | 4.35bn | 8.00bn | 845.00 | 2.08 | 1.43 | 1.83 | 62.51 | 5.07 | 5.07 | 0.1571 | 7.40 | 0.026 | 0.8187 | 2.97 | 147,686.40 | 88.04 | -- | 103.92 | -- | 87.53 | -- | 3,390.53 | -- | 25.10 | -- | 0.0642 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Catalent Inc | 4.14bn | -1.18bn | 10.16bn | 17.80k | -- | 2.80 | -- | 2.46 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | 0.0154 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Viatris Inc | 15.36bn | -56.10m | 12.61bn | 38.00k | -- | 0.6204 | 4.69 | 0.8085 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Incyte Corp | 3.77bn | 745.44m | 13.67bn | 2.52k | 17.92 | 2.46 | 15.95 | 3.52 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 15.59bn | 3.40k | 77.83 | 3.08 | 50.24 | 6.32 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7116 | 3.54 | 0.8079 | 79.22 | 76.30 | 8.31 | 2.05 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Royalty Pharma plc | 2.24bn | 798.86m | 15.65bn | 89.00 | 14.52 | 1.80 | 12.98 | 6.91 | 1.78 | 1.78 | 3.73 | 14.41 | 0.1348 | -- | 73.80 | 25,152,370.00 | 7.15 | 9.57 | 9.60 | 12.42 | -- | -- | 53.01 | 67.80 | -- | -- | 0.3836 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 37.96m | 8.42% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 36.74m | 8.15% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 31.19m | 6.92% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 16.66m | 3.70% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 15.37m | 3.41% |
| Viking Global Investors LPas of 31 Mar 2024 | 11.49m | 2.55% |
| Adage Capital Management LPas of 31 Mar 2024 | 10.82m | 2.40% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.10m | 2.02% |
| Swedbank Robur Fonder ABas of 31 Mar 2024 | 8.28m | 1.84% |
| Geode Capital Management LLCas of 31 Mar 2024 | 6.55m | 1.45% |
